Director Vallerie McLaughlin of Clene Inc. filed a Statement of Changes in Beneficial Ownership on November 13, 2026, reporting the acquisition of a stock option granted on November 12, 2026.

Key Highlights

  • Reporting person: Vallerie McLaughlin, identified as a Director of Clene Inc. (NASDAQ:CLNN)
  • Option grant date: November 12, 2026, with an expiration date of November 11, 2036
  • Shares covered: 3,395 shares of common stock underlying the stock option
  • Exercise price: $4.00 per share, with a derivative security price of $0
  • Vesting: According to the filing, "the options vest immediately upon grant"
  • Plan: The option was granted under the Clene Inc. Amended 2020 Stock Plan
  • Beneficial ownership following transaction: 3,395 derivative securities held directly

McLaughlin Receives Immediately Vesting Stock Option Under Clene's 2020 Plan

According to the filing, Vallerie McLaughlin, a director of Clene Inc., received a stock option on November 12, 2026, covering 3,395 shares of common stock. The option was granted under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.00 per share and carries an expiration date of November 11, 2036. The filing notes that the option, recorded as transaction code "A" (acquired), vests immediately upon grant. The price of the derivative security is listed as $0.

Clene Inc. is a clinical-stage biopharmaceutical company whose common stock trades on NASDAQ under the symbol CLNN. The company's equity compensation activity, such as director option grants of this type, is governed by its Amended 2020 Stock Plan, as referenced in the explanation of responses included in this filing. Following the reported transaction, McLaughlin beneficially owns 3,395 derivative securities directly, with no non-derivative securities reported in Table I of the filing. The filing was signed by Jerome T. Miraglia as power of attorney on November 13, 2026.

What Was Disclosed

The filing reports a single stock option grant to Director Vallerie McLaughlin on November 12, 2026, covering 3,395 shares of Clene Inc. common stock at an exercise price of $4.00 per share, vesting immediately, and expiring November 11, 2036, under the Clene Inc. Amended 2020 Stock Plan.